-
Let’s go
#viral by spreading awareness - today is#WorldInfluenzaDay! Atriva commits to#fightflu with our first-in-class host-targeting MEK inhibitor#ATR002. We address the need for a novel, broadly active, resistance-avoiding therapy and for a prolonged treatment window.pic.twitter.com/DxGvbFPfNV
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.